Comment
Author: Admin | 2025-04-28
And mild severity. These findings align with those of a literature review and meta-analysis [7]. This is a crucial outcome and encouraging news that supports transitioning from monotherapy to the combination.The strengths of our study include a robust sample size, complete retention with no loss to follow-up, and its implementation in a region of Uganda that is highly representative of the contexts where this combination therapy could have the greatest impact, given the high prevalence of STH [20]. Limitations of our trial include it not having been double-blinded, and having a very low number of hookworm cases, which prevents us from drawing conclusions about the efficacy of either treatment arm for this particular parasite. In addition to its superior efficacy against T. trichiura and A. lumbricoides and its equivalent safety profile, we believe the ivermectin-albendazole combination will offer several other significant advantages over albendazole monotherapy. First, it may help delay the development of drug resistance. Second, by more effectively reducing the worm burden in individuals, the combination therapy could lower transmission rates of these parasites [4]. Finally, the use of ivermectin in addition to albendazole also targets other neglected tropical diseases, such as onchocerciasis, lymphatic filariasis, strongyloidiasis and scabies [21,22].In conclusion, we believe a shift from preventive chemotherapy using albendazole alone to using the combination treatment in Uganda is justified, particularly in districts where T. trichiura and A. lumbricoides infections dominate [20]. The FACE-IT project’s next step will be to explore how to best integrate ivermectin-albendazole co-administration in the existing
Add Comment